Am­gen los­es its bid to de­lay biosim­i­lars as SCO­TUS hands No­var­tis a vic­to­ry

Am­gen took their ar­gu­ment that its biosim­i­lar ri­vals should be forced to de­lay their 180-day mar­ket­ing no­tices un­til af­ter the FDA had made up its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.